ID

42024

Description

Study documentation part: Pre-Treatment This is a phase III study of BMS-354825 in subjects with chronic myelogenous leukemia in accelerated phase, or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia who are resistant or intolerant to imatinib mesylate (Gleevec).Trial Number: NCT00123487. Drug: dasatinib. Phase 3.

Mots-clés

Versions (4)

1. 6/7/15 6/7/15 -
2. 6/8/15 6/8/15 -
3. 15/3/21 15/3/21 - Dr. rer. medic Philipp Neuhaus
4. 20/9/21 20/9/21 -

Téléchargé le

15 de marzo de 2021

DOI

Pour une demande vous connecter.

Licence